Product category:
Reagents and catalysts
News Release from: Randox Laboratories | Subject: DoA Array II
Edited by the Laboratorytalk Editorial
Team on 29 January 2008
Biochip screens urine for drugs of abuse
Randox Laboratories's second biochip for drugs of abuse (DoA) screening simultaneously tests for six opioid analgesics including Fentanyl, as well as Ketamine, LSD, Methaqualone and Ecstasy (MDMA)
The release of Randox's DoA II array follows the success of the DoA Array I for barbiturates, amphetamines, cocaine, opiates and cannabinoids Each 9x9mm biochip contains an array of ten discrete test regions of immobilised antibodies specific to different drugs of abuse
This article was originally published on Laboratorytalk on 12 Aug 2005 at 8.00am (UK)
Related stories
Biochip technology comes to the routine lab
Latest innovation in multi-analyte biochip array technology is described as the perfect candidate for profiling drugs of abuse or cytokine arrays
A CCD (charge-coupled device) camera detects the chemiluminescent signal generated by each test region and advanced image-processing software reads all ten test results simultaneously.
Both arrays include an eleventh test, creatinine, to identify adulterated urine samples.
Three different biochips are designed for DoA Array I, each optimised for a different matrix: blood, urine and oral fluid.
DoA Array II is available for urine screening; blood and oral fluid biochips currently in development.
The fully automated evidence analyser offers a rapid, consistent and cost-effective system for high-throughput drugs of abuse screening.
The semi-automated Evidence Investigator is designed for low-throughput screening and research applications. Request a free brochure from Randox Laboratories ...
• Randox Laboratories: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
